• Clinical Insights: April 6, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Roszet™ (ezetimibe and rosuvastatin) Tablets – New Drug Approval – March 23, 2021 – Althera Pharmaceuticals, a company focused on heart health, today announced the FDA approval of Roszet™… Read more »

  • Clinical Insights: March 30, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Abecma™ (idecabtagene vicleucel) Suspension for Intravenous Infusion – New Drug Approval – March 26, 2021 – Bristol Myers Squibb and bluebird bio, Inc. announced that the U.S. Food and… Read more »

  • Clinical Insights: March 23, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Ponvory™ (ponesimod) Tablets – New Drug Approval – March 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA)… Read more »

  • Clinical Insights: March 16, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Fotivda™ (tivozanib) – New Drug Approval – March 10, 2021 – The Food and Drug Administration approved tivozanib (Fotivda™, Aveo Pharmaceuticals, Inc.), a kinase inhibitor, for adult patients… Read more »

  • Clinical Insights: March 9, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Azstarys™ (dexmethylphenidate and serdexmethylphenidate) Capsules – New Drug Approval – March 2, 2021 – KemPharm, Inc., a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,… Read more »

  • Clinical Insights: March 2, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Nulibry™ (fosdenopterin) Injection – New Drug Approval – February 26, 2021 – The U.S. Food and Drug Administration approved Nulibry™ (fosdenopterin) for injection to reduce the risk of… Read more »

  • Clinical Insights: February 23, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Formulation Approval No new update. New Indication/Dosage Approval Entresto® (sacubitril and valsartan) Tablets – New Approved Indication – February 16, 2021 – Novartis announced… Read more »

  • Clinical Insights: February 16, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval CoselaTM (trilaciclib) – New Drug Approval – February 12, 2021 – The U.S. Food and Drug Administration approved CoselaTM (trilaciclib) as the first therapy in its class to… Read more »

  • Clinical Insights: February 9, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval BreyanziTM (lisocabtagene maraleucel) – New Drug Approval – February 5, 2021 – The U.S. Food and Drug Administration approved BreyanziTM (lisocabtagene maraleucel), a cell-based gene therapy to treat… Read more »

  • Clinical Insights: February 2, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more. New Drug Approval No new update. New Formulation Approval No new update. New Indication/Dosage Approval Plegridy® (peginterferon beta-1a) Injection – New Approved Route of Administration – January 29, 2021 – Biogen… Read more »